Insider Selling: LifeStance Health Group (NASDAQ:LFST) CTO Sells $481,674.90 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFSTGet Free Report) CTO Vukasin Paunovich sold 44,394 shares of LifeStance Health Group stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $481,674.90. Following the transaction, the chief technology officer owned 247,446 shares in the company, valued at approximately $2,684,789.10. This trade represents a 15.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

LifeStance Health Group Trading Up 1.6%

Shares of LFST stock opened at $12.42 on Friday. LifeStance Health Group, Inc. has a 52-week low of $4.77 and a 52-week high of $12.76. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. The firm has a market capitalization of $4.82 billion, a PE ratio of 95.55 and a beta of 1.14. The stock has a fifty day simple moving average of $10.39 and a two-hundred day simple moving average of $8.22.

LifeStance Health Group (NASDAQ:LFSTGet Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The business had revenue of $435.35 million for the quarter, compared to analysts’ expectations of $414.58 million. During the same period last year, the firm earned ($0.01) earnings per share. The business’s quarterly revenue was up 26.1% on a year-over-year basis. On average, analysts predict that LifeStance Health Group, Inc. will post 0.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LFST. Larson Financial Group LLC increased its holdings in shares of LifeStance Health Group by 19,952.6% in the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after purchasing an additional 3,791 shares during the last quarter. KBC Group NV bought a new position in LifeStance Health Group during the first quarter valued at approximately $29,000. EverSource Wealth Advisors LLC grew its holdings in LifeStance Health Group by 359.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after buying an additional 5,404 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in LifeStance Health Group by 615.3% during the first quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock valued at $59,000 after purchasing an additional 7,987 shares during the last quarter. Finally, Assetmark Inc. lifted its position in LifeStance Health Group by 17.0% during the first quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after purchasing an additional 1,367 shares during the last quarter. Hedge funds and other institutional investors own 85.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LFST. KeyCorp lifted their target price on LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Wall Street Zen upgraded LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday. JPMorgan Chase & Co. increased their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a report on Friday. Barclays lifted their price objective on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. Finally, Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $12.12.

Get Our Latest Stock Report on LFST

About LifeStance Health Group

(Get Free Report)

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

Recommended Stories

Insider Buying and Selling by Quarter for LifeStance Health Group (NASDAQ:LFST)

Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.